Pfizer Inc. recently announced positive top-line data from the ongoing pivotal Phase 3 clinical trial evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years of age at risk of developing severe... READ →
Precision Vaccinations
/ April 26th, 2024Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.